Does administration of iodinated contrast agent interfere with a technetium-99m DTPA (diethylenetriamine pentaacetate) renal scan?

Iodinated Contrast Does Not Interfere with Tc-99m DTPA Renal Scans

There is no evidence that iodinated contrast agent administration interferes with technetium-99m DTPA renal scintigraphy, and these studies can be performed sequentially when clinically indicated.

Mechanism and Pharmacokinetics

The two agents operate through completely different mechanisms without pharmacologic interaction:

• Tc-99m DTPA is cleared exclusively by glomerular filtration (extraction fraction ~20%) and distributes only in the extracellular fluid space with minimal protein binding (3.7-10%) 1
• Iodinated contrast is also cleared renally but does not chemically or pharmacologically interfere with DTPA's biodistribution or renal handling

The FDA label for Tc-99m DTPA contains no contraindications or warnings regarding prior iodinated contrast administration 1.

Clinical Practice Evidence

Multiple ACR Appropriateness Criteria guidelines discuss both modalities in the same clinical pathways without any mention of interference or required waiting periods:

• Renal transplant evaluation: Both CT with iodinated contrast and DTPA scans are listed as appropriate imaging options without restrictions on sequential use 2
• Hydronephrosis workup: CTU (requiring iodinated contrast) and DTPA renal scans are both appropriate diagnostic tools, with no guidance suggesting they cannot be performed in proximity 3
• Antenatal hydronephrosis: Guidelines discuss both VCUG (using iodinated contrast) and DTPA scans as complementary studies without timing restrictions 4

Important Caveats

Renal Function Considerations

The primary concern is not interference between agents, but rather protecting renal function when using iodinated contrast:

• In patients with GFR <60 mL/min/1.73 m², follow KDIGO guidelines for contrast administration: use lowest dose, ensure adequate hydration, avoid high-osmolar agents 5
• Contrast-induced nephropathy could theoretically alter subsequent DTPA scan results by changing renal function itself—not through direct agent interference 6

Timing Strategy

While not required for avoiding interference, consider this practical approach:

• If both studies are needed urgently, perform DTPA scan first when possible to establish baseline renal function before any potential contrast-related changes
• If contrast study must come first, ensure adequate hydration (48-96 hours) and reassess renal function before DTPA scan if there are risk factors for contrast nephropathy 5

MAG3 Preference

Note that Tc-99m MAG3 is generally preferred over DTPA for diuretic renography due to higher extraction fraction (40-50% vs 20%) and better image quality, particularly in patients with reduced renal function 3, 4. This preference exists independent of any contrast considerations.

Practical Algorithm

1. Normal renal function (GFR >60): Perform studies in any order based on clinical urgency
2. Impaired renal function (GFR <60):
   • Ideally perform DTPA scan first
   • If contrast CT needed first, follow KDIGO hydration protocols
   • Reassess creatinine 48-96 hours post-contrast before DTPA if high nephropathy risk
3. Dialysis patients: No restrictions—both agents can be used 5, 7

The concern should focus on preserving renal function when using iodinated contrast, not on direct interference between the two agents.